Director, Clinical Supply Chain

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It’s an exciting time to be part of Team Olema , with our transfor mation into a fully integrated oncology company well underway , t op-line data from our lead program expected later this year , and our first potential commercial launch on the horizon.

Our lead product candidate,palazestrant, isa novel, orallyavailablecomplete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently intwopivotal

Phase 3clinicaltrials.

We expect top-line data from OPERA-01,our ongoing

Phase 3 trial ofpalazestrantas a monotherapy in patients with second- or third-lineER+/HER2-metastatic breast cancer (MBC), in the fallwhich, if successful, could lead to our first potential approval and commercial launchin 2027. OPERA-02,our Phase 3 trial ofpalazestrantin combination withribociblibin patients with frontlineER+/HER2- MBC, is enrolling patients.

Togetherwith its mechanism of action, pharmacokinetic properties,andthe potential todemonstrateactivity in bothESR1wild-type and mutant tumors,palazestranthas the potential to transform the metastatic breast cancer treatment paradigm andaccessa $15 billion global market opportunity.

Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor withthepotential to generate further value and meaningfullyimpactthemetastatic breastcancertreatment landscape – particularly in combination withpalazestrant.

We recently reported encouraging

Phase 1monotherapydata from this program across multiple solid tumor types andareadvancingpatientenrollment in theongoingcombinationarmsin MBC.

Aspiring to transform the metastatic treatment paradigm an ambitious endeavor that requires aresolute approach to developing better therapies and apassionateteamdedicated tohelping the patients we serve feel better,longer.

Wepossessadeepcommitment toour shared purpose,the sustained pursuit of excellence, cultivatingthecouragerequiredto advance our programs, drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. Team Olema is made up of nimble self-starters who bring consistency in their quest for the extraordinary every single day.

Ifyou’rereadyto bepart of atenacious,courageous,agile, andgrowingteam,join us in makinga profound impact,together–
for our patients, for your career, and for what’s beyond .

About the Role >>>
Director, Clinical Supply Chain

As a Director, Clinical Supply Chain reporting to the Vice President Clinical Supply Chain, you will have oversight of all aspects of the clinical supply chain to ensure uninterrupted and timely clinical drug supply for one of Olema’s largest, late phase clinical programs. This highly cross-functional role will partner closely with Clinical Operations, CMC/Technical Operations, Quality, Regulatory, and external vendors to support study execution and ensure clinical supply readiness as programs advance toward registration and commercialization.

This hands-on role requires an independent self-starter with extensive experience in end-to-end clinical supply chain management.

The role will be based out of either our
San Francisco or our Cambridge office
and require occasional travel
.

Your work will primarily encompass:

• Lead end-to-end clinical supply chain strategy and execution for a global, late-stage clinical program
• Provide technical, functional, and program leadership across clinical supply planning and execution, including alignment with manufacturing and release schedules and direct oversight of CDMOs and other external partners
• Develop and implement global Clinical Supply Chain strategies and deliver…